|
|
|
Hair Loss Study Abstract: Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and aethinyloestradiol women with virilising symptoms
|
Title
[Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and
aethinyloestradiol women with virilising symptoms (author's transl)]
Original Title
Klinische Erfahrungen mit einem niedrig dosierten Antiandrogen (Cyproteronazetat) und
Athinylöstradiol bei Frauen mit Virilisierungserscheinungen
Author
Schmidt-Elmendorff H; Steyer M
Source
Geburtshilfe Frauenheilkd, 37: 4, 1977 Apr, 297-303
Abstract
The paper refers to 167 patients who were treated with 2 mg Cyproteronacetate and 50 mug
Ethinyloestradiol because of acne, seborrhoea, hirsutism and androgenetic alopecia. The
application was daily from the 5th to the 25th day of cycle over a period of 12 months.
The success of treatment depended on the severity of virilisation: in cases of light acne
only 77% of the patients showed improvement, while in cases of severe acne 91,4% showed
improvement or healing of acne. The corresponding figures for seborrhoea were 55,7% and
89,4% respectively, and for hirsutism 37,4% and 60,9% respectively. Furthermore the
success of treatment of the different virilising symptoms depended on the duration of
therapy: while acne was already cured significantly after 6 months of treatment,
seborrhoea and hirsutism show continuous improvement up to the 10th month thetherapy.
Concerning side effects during therapy spottings and brake through bleedings were
registered in 17,1 and 6% of cycles respectively. 16,2% of the patients noted breast
tensions. Finally 68,7% of the patients suffered from nervousness, a very subjective
symptom, which might be explained by the psychic lability accompanying virilising
symptoms. The drop out rate was 7,8%, being not higher than with other oral
contraceptives.
Language of Publication
German
Unique Identifier
77163234
content2 |
|
